Sanofi

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Sanofi (SNY) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Moving Average Crossover Alert: Sanofi

Regeneron Pharmaceuticals

Regeneron (REGN) and Sanofi get positive CHMP recommendation for the label expansion of asthma drug Dupixent in an additional indication.

Regeneron/Sanofi Gets Positive CHMP Opinion for Dupixent

Sanofi (SNY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Sanofi (SNY) Soars to 52-Week High, Time to Cash Out?

AbbVie

Gilead Sciences

Eli Lilly

Novo Nordisk

Patents and monopolies don’t always go hand in hand.

An Investor's Guide to Disrupting Drugmakers

Abbott Labs

Abbott (ABT) collaborates with Sanofi to revolutionize diabetes care through technological advancements.

Abbott Partners With Sanofi to Upgrade Diabetes Management

A commonly used heartburn medicine from Sanofi, known as Zantac, could contain cancer-causing substances, the Food and Drug Administration said Friday. But Sanofi stock rose a fraction.

Popular Sanofi Heartburn Drug Could Contain Carcinogens, FDA Says

Lexicon Pharmaceuticals

Lexicon Pharmaceuticals Inc.’s (NASDAQ: LXRX) shares made a huge gain on Wednesday after the announcement that its alliance with Sanofi (NASDAQ: SNY) was terminated.

What’s Left After Lexicon’s Terminated Partnership With Sanofi

Lexicon Pharmaceuticals (LXRX) settles with Sanofi related to termination of their alliance for development of Zynquista in type I and type II diabetes.

Lexicon (LXRX) Settles With Sanofi for $260M, Shares Rally

Regeneron (REGN) and partner Sanofi get a favorable ruling against Amgen in the ongoing litigation of Praluent.

Regeneron-Sanofi Get Favorable Ruling Against Amgen in Court

Amgen

A U.S. judge on Wednesday set aside a jury verdict that found Amgen Inc  patents on its cholesterol drug Repatha were valid, handing a victory to Regeneron Pharmaceuticals Inc  and Sanofi SA , which sells a rival drug.

U.S. judge rules for Regeneron, Sanofi in Amgen cholesterol drug patent fight

Sanofi reported a substantial revenue boost, but non-recurring items had a negative impact on net income.

Sanofi: Look Through The Impairment Charges To See The True Underlying Value

Assessing An Investment In Sanofi

Dick's Sporting Goods

Realty Income Corp

Sanofi, Realty Income, and Dick's Sporting Goods might just serve up more refreshing returns than the beverage giant.

3 Dividend Stocks  That Pay You More Than Pepsi Does.

Pfizer

SNY vs. PFE: Which Stock Is the Better Value Option?

Sanofi S.A. (SNY) CEO Olivier Brandicourt on Q2 2019 Results - Earnings Call Transcript

Sanofi (SNY) beats estimates for second-quarter earnings. Key immunology drug Dupixent drives sales.

Sanofi (SNY) Q2 Earnings Top, Dupixent Shines, EPS View Up

Sanofi (NYSE: SNY) shares are trading higher after the company reported better-than-expected second-quarter earnings.

Sanofi Trades Higher On Q2 Earnings Beat

Sanofi SA (NYSE: SNY) unveils its next round of earnings Monday, July 29. Here is Benzinga's everything-that-matters guide for the earnings announcement.

Sanofi's Earnings: A Preview

Sanofi (SNY) stock is down 1.8% in 2019 and has been volatile most of the year. Will this slight cumulative downtrend turn around after SNY reports Q2 earnings?

What to Expect from Sanofi's (SNY) Q2 Earnings (Revised)

The French drugmaker says a shipment of its vaccines will begin in mid-August, with all shipments expected to be completed by the end of November.

Sanofi expects one-month delay of vaccine shipments for fall flu season

What to Expect from Sanofi's (SNY) Q2 Earnings

Bayer AG

Merck

Roche Holding AG

Large-Cap Pharmaceuticals Industry Near-Term Outlook Bright

SNY or PFE: Which Is the Better Value Stock Right Now?

The FDA accepts for review Sanofi's (SNY) BLA for isatuximab as a potential treatment for relapsed/refractory multiple myeloma. The FDA will declare its decision by April 2020.

FDA Accepts Sanofi's BLA for Myeloma Candidate to Review

Teva Pharmaceutical

The recent ruling by a federal court against the Trump regime's decree to disclose the price labels of drugs in TV adverts resumes the spotlight on drug pricing.

News for Sanofi Stock (SNY)